Wall Street is positive on Arcutis Biotherapeutics Inc (ARQT). On average, analysts give the stock a Strong Buy rating. The average price target is $47, which means analysts expect the stock to climb by 56.67% over the next twelve months.
That average ranking earns the stock an Analyst Rating of 81, which is better than 81% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.
Investors Observer combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.
What's Happening With Arcutis Biotherapeutics Inc Stock Today?
Arcutis Biotherapeutics Inc (ARQT) stock is trading at $30.00 as of 10:32 AM on Tuesday, May 26, a gain of $0.42, or 1.42% from the previous closing price of $29.58. Volume today is above average. So far 147,599 shares have traded compared to average volume of 53,317 shares. The stock has traded between $29.83 and $31.76 so far today.
